BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Anik Ilhan G, Yildizhan B, Pekin T. The impact of lipid accumulation product (LAP) and visceral adiposity index (VAI) on clinical, hormonal and metabolic parameters in lean women with polycystic ovary syndrome. Gynecol Endocrinol 2019;35:233-6. [PMID: 30303693 DOI: 10.1080/09513590.2018.1519794] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Dumesic DA, Abbott DH, Sanchita S, Chazenbalk GD. Endocrine-Metabolic Dysfunction in Polycystic Ovary Syndrome: an Evolutionary Perspective. Curr Opin Endocr Metab Res 2020;12:41-8. [PMID: 32363240 DOI: 10.1016/j.coemr.2020.02.013] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
2 Bermúdez V, Salazar J, Fuenmayor J, Nava M, Ortega Á, Duran P, Rojas M, Añez R, Rivas-Montenegro A, Angarita L, Chacín M, Cano C, Velasco M, Rojas J. Lipid Accumulation Product Is More Related to Insulin Resistance than the Visceral Adiposity Index in the Maracaibo City Population, Venezuela. J Obes 2021;2021:5514901. [PMID: 34194826 DOI: 10.1155/2021/5514901] [Reference Citation Analysis]
3 Zheng S, Tong M, Dong L, Du C, Zheng X, Wang L, Huang P, Liu W, Lin M, Liu C. Lipid accumulation product independently correlate with hepatic steatosis quantified by controlled attenuation parameter in women with polycystic ovary syndrome. Endocr Connect 2020;9:154-62. [PMID: 31910158 DOI: 10.1530/EC-19-0559] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
4 Dumesic DA, Phan JD, Leung KL, Grogan TR, Ding X, Li X, Hoyos LR, Abbott DH, Chazenbalk GD. Adipose Insulin Resistance in Normal-Weight Women With Polycystic Ovary Syndrome. J Clin Endocrinol Metab 2019;104:2171-83. [PMID: 30649347 DOI: 10.1210/jc.2018-02086] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 12.5] [Reference Citation Analysis]
5 Durcan E, Sahin S, Dedeoglu SE, Ozkaya HM, Gonen MS. Can "VAI" Better Indicate Metabolic Syndrome Compared with Other Metabolic Syndrome-Related Parameters in Patients with Thyroid Nodules? A Study from Turkey. Metab Syndr Relat Disord 2021;19:358-66. [PMID: 33794138 DOI: 10.1089/met.2020.0147] [Reference Citation Analysis]
6 Demirbas N, Kutlu R. Importance of Measured Body Fat, Visceral Adiposity Index, and Lipid Accumulation Product Index in Predicting Cardiometabolic Risk Factors. Metab Syndr Relat Disord 2021;19:174-9. [PMID: 33121374 DOI: 10.1089/met.2020.0098] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Ataseven A, Kutlu R, Uzun L. The relation between visceral fat markers and cardiometabolic disease risks in psoriasis patients. North Clin Istanb 2021;8:203-11. [PMID: 34222799 DOI: 10.14744/nci.2020.41961] [Reference Citation Analysis]